ORIGINAL RESEARCH article
Front. Med.
Sec. Ophthalmology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1606985
A Novel Strategy for the Management of Cytomegalovirus Retinitis in Immunocompromised Patients Using New Anti-Cytomegalovirus Drugs
Provisionally accepted
- Department of Ophthalmology, Peking University People’s Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: This study presents four cases of cytomegalovirus retinitis (CMVR) managed using a novel antiviral strategy, aiming to preliminarily assess its efficacy and safety profile. Methods: A retrospective chart review was conducted on four patients (seven eyes) diagnosed with CMVR at Peking University People's Hospital. All patients received oral letermovir or maribavir as the primary treatment. Weekly intravitreal injections of high-dose (6mg) ganciclovir (IVG) were administered to those with macula involvement or aggressive lesions during the initial treatment. Data on demographics, ophthalmic examinations, laboratory results, and clinical outcomes were analyzed. Results: All four patients showed clinical and fundoscopic improvement, achieving complete resolution of retinitis. However, one patient developed bilateral retinal detachment requiring vitrectomy. Initial administration of high-dose IVG ensured rapid stabilization of the aggressive or macula-threatening lesions. While subsequent oral antiviral maintenance significantly reduced the need for repeated IVG injections. Both letermovir and maribavir demonstrated excellent tolerability with no adverse events observed. Conclusions: This novel therapeutic strategy provides safe and effective treatment option for CMVR, particularly promising for patients with complex systemic comorbidities.
Keywords: Novel strategy, antiviral, Cytomegalovirus Retinitis, Letermovir, Maribavir
Received: 09 Apr 2025; Accepted: 29 May 2025.
Copyright: © 2025 Yao, Zeng, Sun, Jin, Tang, Cai, Hou and Miao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Heng Miao, Department of Ophthalmology, Peking University People’s Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.